VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Sandra Demaria on Radiation and Immunotherapy Combination Regimens

Sandra Demaria, MD
Published: Friday, Jun 10, 2016

Sandra Demaria, MD, assistant professor of Radiation Oncology, (Interim), Radiation Oncology, Weill Cornell Medical College and New-York Presbyterian, discusses the synergy with radiation therapy and immunotherapy as a potential combination regimen for patients with cancer.

Radiation therapy has various effects on patients depending on the way it is administered, Demaria explains. Nevertheless, there is a synergy that exists between radiation therapy and immunotherapy that has an effect on the tumor microenvironment.

Evidence suggests that T-cell responses can occur with such a combination, she adds, while ongoing research is examining additional immunotherapy and radiation therapy agents. This is particulary interesting, Demaria says, because radiation therapy is readily available; however, it could now be administered in a completely different way to induce a systemic effect on tumors.
 
Sandra Demaria, MD, assistant professor of Radiation Oncology, (Interim), Radiation Oncology, Weill Cornell Medical College and New-York Presbyterian, discusses the synergy with radiation therapy and immunotherapy as a potential combination regimen for patients with cancer.

Radiation therapy has various effects on patients depending on the way it is administered, Demaria explains. Nevertheless, there is a synergy that exists between radiation therapy and immunotherapy that has an effect on the tumor microenvironment.

Evidence suggests that T-cell responses can occur with such a combination, she adds, while ongoing research is examining additional immunotherapy and radiation therapy agents. This is particulary interesting, Demaria says, because radiation therapy is readily available; however, it could now be administered in a completely different way to induce a systemic effect on tumors.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x